Imprimis Pharmaceuticals (NSDQ:IMMY) touted data today from a peer-reviewed study of patients who received its “dropless therapy” following cataract surgery.
The San Diego-based company uses a compounded antibiotic and steroid formulation in single, injectable doses administered by physicians following ocular surgery. The treatment is designed to eliminate the need for patient-administered eye drops, potentially eliminating patient non-compliance or dosing errors. The compounded formulations use Imprimis’ patent-pending SSP technology, which helps active pharmaceutical ingredients solubilize into a well-distributed particle suspension.
The 922-patient study showed that in 92% of the cases, eye drops or supplemental medication were not needed after surgery if doctors gave patients the injectable, intraocular dropless therapy.
The paper will be published in January 2017 in Current Opinion in Ophthalmology. The authors reported that there were no major intra-operative complications associated with the injection, no cases of postoperative endophthalmitis, and that mean visual acuity was significantly increased at all postoperative visits, including the day after surgery. They also wrote that the rates of infection and inflammation appear similar to reported rates with alternative therapies like topical drops.
“I have performed over 5,000 cataract surgeries since Imprimis’ Tri-Moxi-Vanc was first introduced and, with the exception of steroid responsive and advanced glaucoma patients, I exclusively use TMV as a prophylactic alternative for my patients undergoing cataract surgery,” study author Dr. Sydney Tyson said in prepared remarks. ” As a result, I have had the opportunity to retrospectively compile and analyze the largest case series to date evaluating the clinical benefits of TMV. Although eye drops have been the current standard of care, there is a paradigm shift occurring as more surgeons are moving to single-use intraocular injections.”
